NCT07324005 Efficacy of Combining Ultrasound-Guided Needle Release of Transverse Carpal Ligament and Median Nerve Dextrose Water Hydrodissection for Carpal Tunnel Syndrome
| NCT ID | NCT07324005 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shin Kong Wu Ho-Su Memorial Hospital |
| Condition | Carpal Tunnel Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 102 participants in total. It began in 2026-01-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Carpal tunnel syndrome (CTS) is a common musculoskeletal disorder, which is caused by compression of the median nerve as it travels through the wrist. There are several treatments for CTS, including conservative and surgical options. Though local corticosteroid injection has been considered more effective than physical therapy for treatment of CTS and has significant short-term benefits, long term benefits are not evidenced. Several studies in recent years reported significantly superior longer-term benefit of D5W and PRP compared with corticosteroid injections and other conservative managements. In addition, percutaneous release of the transverse carpal ligament (TCL) was developed to treat CTS in recent years. Because the effectiveness of the recently developed techniques in treating CTS has not been well established, the investigators aim to investigate whether combining US-guided partial release of the transverse carpal ligament with a needle plus D5W hydrodissection is more beneficial for CTS comparing to either treatment alone.
Eligibility Criteria
Inclusion Criteria: * age between 20 to 80 years old * diagnosed with CTS on the basis of clinical condition and an electrophysiological analysis * the NRS of pain or paresthesia≧3 * with symptoms lasting for a minimum of 3 months. Exclusion Criteria: * history of polyneuropathy, thoracic outlet syndrome, brachial plexopathy, or inflammatory arthropathy * onset of CTS during pregnancy, hypothyroidism, or systemic infection * previous corticosteroid injection or wrist surgery for CTS * hypersensitivity to dextrose injection * the anatomic structure of the wrist is not suitable for needle release of TCL.
Contact & Investigator
Lin-Fen Hsieh
PRINCIPAL INVESTIGATOR
Shin Kong Wu Ho-Su Memorial Hospital
Frequently Asked Questions
Who can join the NCT07324005 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 80 Years, studying Carpal Tunnel Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07324005 currently recruiting?
Yes, NCT07324005 is actively recruiting participants. Contact the research team at M001026@ms.skh.org.tw for enrollment information.
Where is the NCT07324005 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT07324005 clinical trial?
NCT07324005 is sponsored by Shin Kong Wu Ho-Su Memorial Hospital. The principal investigator is Lin-Fen Hsieh at Shin Kong Wu Ho-Su Memorial Hospital. The trial plans to enroll 102 participants.